Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta, Luigi Macchia
{"title":"Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis.","authors":"Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta, Luigi Macchia","doi":"10.1186/s12948-021-00144-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.</p><p><strong>Case presentation: </strong>We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).</p><p><strong>Conclusions: </strong>Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.</p>","PeriodicalId":72604,"journal":{"name":"","volume":"19 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2021-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207639/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-021-00144-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.
Case presentation: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Conclusions: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
